Mouse models of prostate cancer (PCa) are critical for understanding the biology of PCa
initiation, progression, and treatment modalities. Here, we summarize recent advances in …

Angelman syndrome (AS) is a rare neurodevelopmental disorder characterized by
developmental delay, impaired communication, motor deficits and ataxia, intellectual …

Resistant breast and prostate cancers remain a major clinical problem, new therapeutic
approaches and better predictors of therapeutic response are clearly needed. Because of …

Spinobulbar muscular atrophy (SBMA) is an inherited neuromuscular disorder caused by
the expansion of a CAG repeat encoding a polyglutamine tract in exon 1 of the androgen …

Spinal bulbar muscular atrophy (SBMA) is a motor neuron disease caused by toxic gain of
function of the androgen receptor (AR). Previously, we found that co-regulator binding …

A well established functional polymorphism of the human androgen receptor (hAR) is the
length of AR's N-terminal glutamine tract (Q-tract). This tract is encoded by a CAG …

To examine the impact of common somatic mutations in prostate cancer (PCa) on androgen
receptor (AR) signaling, mouse models were designed to perturb sequentially the AR, ETV1 …

Androgen deprivation is the cornerstone of the management of metastatic prostate cancer.
Despite several decades of clinical experience with this therapy there are no standard …

MRI is a powerful modality to detect neuroanatomical differences that result from mutations
and treatments. Knowing which genes drive these differences is important in understanding …

Gain-of-function mutations in the androgen receptor (AR) are found in prostate cancer and
are implicated in the failure of hormone therapy. Most studies have emphasized the ligand …